Latest Breaking News On - Specifict cell product candidate - Page 1 : comparemela.com

Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results - Dosed first patient in the Company s Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product candidate, for the treatment of post-transplant acute myeloid leukemia - - Completed construction of new in-house cGMP manufacturing facility in Houston to supply MultiTAA-specific T cell products, including MT-401, for clinical activities and potential commercialization; facility expected to be fully operational in 1H 2021 - News provided by Share this article Share this article HOUSTON, March 9, 2021 /PRNewswire/  Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the fiscal year ended December 31, 2020.  

United statesPeterl hoangMarker therapeutics incCapital fundMarker therapeuticsMulti antigen targetedSpecifict cell product candidateGeorge bush intercontinentalAspire capital fundAspire capitalPrivate securities litigation reform actOperating activitiesInvesting activitiesFinancing activitiesHealth care amp hospitalsMedical pharmaceuticals